Literature DB >> 8763334

P-glycoprotein--a mediator of multidrug resistance in tumour cells.

U A Germann1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763334     DOI: 10.1016/0959-8049(96)00057-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  77 in total

1.  Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.

Authors:  E J Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.

Authors:  E Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

3.  Lysosome-associated protein transmembrane 4 alpha (LAPTM4 alpha) requires two tandemly arranged tyrosine-based signals for sorting to lysosomes.

Authors:  Douglas L Hogue; Colin Nash; Victor Ling; Tom C Hobman
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

4.  Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.

Authors:  Koji Matsuo; Michele L Eno; Edward H Ahn; Mian M K Shahzad; Dwight D Im; Neil B Rosenshein; Anil K Sood
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

5.  CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages.

Authors:  M E Perkins; Y A Riojas; T W Wu; S M Le Blancq
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

6.  Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.

Authors:  Ritesh Jain; Sridhar Duvvuri; Viral Kansara; Nanda Kishore Mandava; Ashim K Mitra
Journal:  Int J Pharm       Date:  2006-12-03       Impact factor: 5.875

Review 7.  The mechanism of action of multidrug-resistance-linked P-glycoprotein.

Authors:  Z E Sauna; M M Smith; M Müller; K M Kerr; S V Ambudkar
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

8.  Doxorubicin pathways: pharmacodynamics and adverse effects.

Authors:  Caroline F Thorn; Connie Oshiro; Sharon Marsh; Tina Hernandez-Boussard; Howard McLeod; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

9.  Interaction of common azole antifungals with P glycoprotein.

Authors:  Er-jia Wang; Karen Lew; Christopher N Casciano; Robert P Clement; William W Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

10.  Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes.

Authors:  Feng-Ying Huang; Jing Lei; Yan Sun; Fei Yan; Bin Chen; Liming Zhang; Zhuoxuan Lu; Rong Cao; Ying-Ying Lin; Cai-Chun Wang; Guang-Hong Tan
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.